Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

or new therapies that could offer patients less frequent dosing regimens and better tolerability."

The randomized, double-blind, placebo-controlled, in-clinic trial used a cross-over design to evaluate the efficacy, safety and tolerability of three doses of NGX267. A total of 26 patients with xerostomia associated with primary or secondary Sjogren's syndrome were enrolled at three sites in the United States. In four distinct treatment periods, each patient was randomized to receive a single dose of 10 mg, 15 mg and 20 mg of NGX267 and placebo. Patients remained in the clinic and serial efficacy assessments were taken at scheduled time points through 24 hours post dosing. For the primary endpoint, whole mouth salivary flow was collected by passive drainage into pre-weighed containers. Secondary endpoints included maximum change in salivary flow rate compared to predose and an 8-item salivary flow questionnaire completed by the patient that assessed the impact of dry mouth across various dimensions of patient functioning.

The 10 mg, 15 mg and 20 mg doses of NGX267 produced statistically significant increases in salivary flow compared to placebo across a number of time points, including the mean salivary flow production over the 24 hour post-dosing period (p=0.025, 0.001, and 0.001, respectively). In addition, the maximum change in salivary flow was statistically significant compared to placebo for each of the three doses of NGX267. Results of the 8-item patient self-assessment correlated with the quantitative results of salivary production. At the 15 mg and 20 mg doses, statistically significant differences compared to placebo were demonstrated in a variety of domains including items that rated improvement in speaking and swallowing, dryness of mouth and level of thirst.

Safety was monitored throughout the evaluation period and NGX267 was shown to be safe and well-tolerated. All patients completed all tr
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... NEW YORK and VIENNA , ... today at a press conference in New York ... of PD01A, a vaccine against Parkinson,s disease. PD01A is the ... target, to enter clinical testing. The Michael J. ... a $ 1.5 million grant, and presented at the press ...
(Date:7/31/2014)... LONDON , July 31, 2014 genae, ... medical industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in ... and it is projected to increase by a CAGR of 6.0% ... 2012, equal to 9.5% of GDP. Despite recessionary pressures, market growth ...
(Date:7/31/2014)... 2014 Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics ... a conference call on Thursday, August 14, 2014, at 4:30 ... ended June 30, 2014. Financial results will be issued in ... Chairman, President and CEO James LaFrance will host ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... Oct. 14 Cephalon, Inc. (Nasdaq: CEPH ... Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) ... Administration (FDA).  The GABITRIL REMS consists of a Medication ... with the use of GABITRIL.  The implementation of the ...
... SMA ), a leading independent provider of products ... announced today that it will release third quarter 2010 financial ... market opens on Thursday, November 4, 2010. Symmetry Medical will ... Thursday, November 4, 2010. A live Web ...
Cached Medicine Technology:Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL 2Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL 3Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL 4Symmetry Medical to Report Third Quarter 2010 Financial Results on November 4, 2010 2
(Date:7/31/2014)... Adventist Health System, which is ... Florida Hospital Tampa, Florida Hospital Carrollwood, Florida Hospital ... Pinellas, Florida Hospital Wesley Chapel, Florida Hospital Zephyrhills, ... Heartland Medical Center Lake Placid and Florida Hospital ... Most Wired Hospitals and Health Systems, which is ...
(Date:7/31/2014)... 2014 Hook Your Ex, a system created by ... feel emotionally hungry for their partner, to the point of starvation, ... little trick has been taught to hundreds of men and women ... Hook Your Ex review , Shane Michaels agrees this simple trick ... a breakup a second chance at getting back together with their ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary is ... Anthony Le Donne and Peter J. Bellini. Both began ... to United is a Director of Non-Degree Programs, Mark ... , Anthony Le Donne, Assistant Professor of New Testament, ... teaches New Testament, Second Temple Judaism, and Greek courses. ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Cosmetic Town ... best Plastic Surgeons to consumers considering cosmetic treatments. ... their peers whose goal is to educate prospective patients ... are selected through a validated referral system that helps ... the best in their respective fields. , Cosmetic ...
(Date:7/31/2014)... The VitaSleep FDA cleared anti-snoring device ... an easier breathing capacity by slightly adjusting the position ... can breathe easier and helps reduce or even completely ... it can meet the needs of each individual snorer. ... by actual customer reviews. Johathan R. from Statham ...
Breaking Medicine News(10 mins):Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Growing Seminary Welcomes New Faculty 2Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2
... 2011) The Lymphoma Division of the John Theurer Cancer ... the Facebook groups "Hope for Lymphoma" and "Our MCL Family," ... November 12 from 8:30am 3:45pm. The event is ... Lymphoma (MCL) patients and their caregivers coping with this challenging ...
... EDITOR,S PICK: Connexins: providing protection to cells destroyed in ... a lifelong disease characterized by high levels of sugar ... patient,s immune system attacking and destroying the cells in ... blood glucose levels. Surprisingly, little is known about the ...
... , MONDAY, Nov. 7 (HealthDay News) -- People who believe ... it than those who think the rule has some wiggle room, ... a number of human behaviors and actions, including the Arab Spring ... in an upcoming issue of the journal Psychological Science . ...
... be published online Nov. 6 in Nature Medicine , ... that the development of osteoarthritis is in great part driven ... prevailing view attributing the condition to a lifetime of wear ... said William Robinson, MD, PhD, the study,s senior author, of ...
... Ore. After men become fathers for the first time, ... according to a new, 19-year study. Researchers assessed more ... to 31, and examined how men,s crime, tobacco, alcohol, and ... marriage can change a man,s negative behavior, they had not ...
... undergo radical prostatectomy get better results at teaching hospitals ... of an international study led by researchers at Henry ... that teaching hospitals always provide better care than others, ... characteristics that would explain the better results," says Quoc-Dien ...
Cached Medicine News:Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 3Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:People Seem More Likely to Follow Rules They Can't Beat 2Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 2Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 3Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 4Health News:Fatherhood can help change a man's bad habits 2Health News:Prostate cancer surgery better at teaching hospitals 2
Ties improve torso fit and transfer weight to waist and hips. Ties are 1"W cotton woven for flexibility and sewn at an angle across the full width of the two back sections for durability....
Ties improve torso fit and transfer weight to waist and hips. Ties are 1"W cotton woven for flexibility and sewn at an angle across the full width of the two back sections for durability....
Hip-hugging design transfers weight from shoulders to the hips. Crisscross shoulder design provides snug and comfortable upper torso fit while preventing apron from slipping off shoulders....
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
Medicine Products: